The problem of placebo-controlled trials allowing rescue medication: how to assess efficacy in rhinosinusitis and allergic rhinoconjunctivitis when both groups receive active rescue treatment
Authors:
- Julia VentJVJulia Vent
- Walter LehmacherWLWalter Lehmacher
- 1 June 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 9 (3) , 222-227
Abstract
The assessment of pharmacological efficacy of rhinosinusitis and rhinoconjunctivitis has been performed in various studies involving standardized measures such as symptom scores, various health-related quality of life scales, the sino-nasal outcome test, or the rhinoconjunctivitis quality of life questionnaire. However, the methods and study designs are heterogeneous, and a methodological standard is still lacking. The aim of this review was--from a clinical and a methodological point of view--to evaluate placebo-controlled trials permitting the use of rescue medication and to provide insight into the specific challenges of such clinical trials. Using studies published within the past 24 months as examples, we here demonstrate the problems in evaluating and interpreting these studies and describe possibilities for refining the methodology in order to improve future study designs. The World Allergy Organization has recently published recommendations for the standardization of clinical trials on respiratory allergy in which methodological aspects regarding the use of rescue medication are discussed. This study summarizes the recommendations for study design, outcome measures, and statistical analysis to be used in planning, performing, and analyzing clinical studies on rhinoconjunctivitis and rhinosinusitis that allow the use of rescue medication.Keywords
This publication has 24 references indexed in Scilit:
- Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2009
- Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT studyAllergy, 2008
- Agreement of efficacy assessments for five‐grass pollen sublingual tablet immunotherapyAllergy, 2008
- Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 yearsJournal of Allergy and Clinical Immunology, 2008
- Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5–grass pollen tablet for seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2007
- Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trialsAllergy, 2007
- Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforceAllergy, 2007
- Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2006
- Clinical trials: active control vs placebo — What is ethical?Science and Engineering Ethics, 2004
- Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trialClinical & Experimental Allergy, 2002